In conclusion, in this report we showed that KD033, the anti-human-PD-L1/IL-15 molecule currently in clinical study, had similar anti-tumor efficacies as its mouse surrogate, the anti-mouse-PD-L1/IL-15. The gene discussed is CD274; the disease is neoplasm.